Minerva Neurosciences (NERV) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Retension Pharmaceuticals is the larger company by market cap ($117.2 million vs $112.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | RTSN |
|---|---|---|
| Share price | $2.35 | $14.07 |
| Market cap | $112.21M | $117.23M |
| 1-day change | -2.89% | +15.23% |
| YTD return | -41.54% | — |
| 1-year return | -5.62% | — |
| 5-year return | -76.87% | — |
| EPS (TTM) | $-36.12 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-293.42M | — |
| 52-week high | $12.46 | $14.97 |
| 52-week low | $2.28 | $9.66 |
| Distance from 52-week high | -81.14% | -6.02% |
| Analyst consensus | none | — |
| Avg. price target upside | +339.57% | — |
| Average volume | 181.64K | 252.97K |
| Shares outstanding | 47.75M | 8.33M |
| Employees | 7 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
NERV vs RTSN FAQ
Which is bigger, Minerva Neurosciences or Retension Pharmaceuticals?
Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $117.23M compared with $112.21M for Minerva Neurosciences (NERV).
Are Minerva Neurosciences and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.